Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit

Bharat G Jagiasi[1], Akshaykumar A Chhallani[2], Subhal B Dixit[3], Rishi Kumar[4], Rahul A Pandit[5], Deepak Govil[6], Shirish Prayag[7], Kapil G Zirpe[8], Rajesh C Mishra[9], Gunjan Chanchalani[10], Farhad N Kapadia[11]

Abstract

Deep vein thrombosis (DVT) is a preventable complication of critical illness, and this guideline aims to convey a pragmatic approach to the problem. Guidelines have multiplied over the last decade, and their utility has become increasingly conflicted as the reader interprets all suggestions or recommendations as something that must be followed. The nuances of grade of recommendation vs level of evidence are often ignored, and the difference between a "we suggest" vs a "we recommend" is overlooked. There is a general unease among clinicians that failure to follow the guidelines translates to poor medical practice and legal culpability. We attempt to overcome these limitations by highlighting ambiguity when it occurs and refraining from dogmatic recommendations in the absence of robust evidence. Readers and practitioners may find the lack of specific recommendations unsatisfactory, but we believe that true ambiguity is better than inaccurate certainty. We have attempted to comply with the guidelines on how to create guidelines.[1] And to overcome the poor compliance with these guidelines.[2] Some observers have expressed concern that DVT prophylaxis guidelines may cause more harm than good.[3] We have placed greater emphasis on large randomized controlled trials (RCTs) with clinical end point and de-emphasized RCTs with surrogate end points and also de-emphasized hypothesis generating studies (observational studies, small RCTs, and meta-analysis of these studies). We have de-emphasized RCTs in non-intensive care unit populations like postoperative patients or those with cancer and stroke. We have also considered resource limitation settings and have avoided recommending costly and poorly proven therapeutic options.

Keywords: Acute pulmonary embolism, Deep vein thrombosis, Guidelines, Intensive care unit mortality.

Indian Journal of Critical Care Medicine (2022): 10.5005/jp-journals-10071-24195

Executive Summary

Preamble

Deep vein thrombosis is a preventable complication of critical illness, and this consensus statement aims to convey a pragmatic approach to the problem based on the combination of evidence and agreement among all committee members.

Guidelines have multiplied over the last decade, and their utility has become increasingly conflicted as the reader interprets all suggestions or recommendations as something that must be followed. The nuances of the grade of recommendation vs the level of evidence are often ignored, and the difference between a "we suggest" vs a "we recommend" is overlooked. There is a general unease among clinicians, that failure to follow the guidelines translates to poor medical practice and legal culpability.

An expert panel consisting of experienced intensivists was formed to critically appraise the available literature on prevention of venous thromboembolism (VTE) in critically ill patients. We attempted to overcome the above-mentioned limitations of guidelines by highlighting ambiguity when it occurs and refraining from dogmatic recommendations in the absence of robust evidence. Readers and practitioners may find the lack of specific recommendations unsatisfactory, but we believe that true ambiguity is better than inaccurate certainty. We have attempted to comply with the guidelines on how to create guidelines[1] and to overcome the poor compliance with these guidelines.[2] Some observers have expressed concern that DVT prophylaxis guidelines may cause more harm than good.[3] We have placed

[1]Critical Care Department, Reliance Hospital, Navi Mumbai, Maharashtra, India

[2]Akshjyot Clinic, Mumbai, Maharashtra, India

[3]Department of Critical Care, Sanjeevan and MJM Hospital, Pune, Maharashtra, India

[4]Department of Critical Care, PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India

[5]Critical Care, Fortis Hospital, Mumbai, Maharashtra, India

[6]Institute of Critical Care and Anesthesia, Medanta – The Medicity, Gurugram, Haryana, India

[7]Critical Care, Prayag Hospital, Pune, Maharashtra, India

[8]Neuro Trauma Unit, Grant Medical Foundation, Pune, Maharashtra, India

[9]Department of MICU, Shaibya Comprehensive Care Clinic, Ahmedabad, Gujarat, India

[10]KJ Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India

[11]Hinduja Hospital, Mumbai, Maharashtra, India

Corresponding Author: Bharat G Jagiasi, Critical Care Department, Reliance Hospital, Navi Mumbai, Maharashtra, India, Phone: +91 9766363200, e-mail: bharatjagiasi@yahoo.com

greater emphasis on large RCTs with clinical end point on the topic and understated RCTs with having DVT as surrogate end points and also downplayed hypothesis generating studies (observational studies, small RCTs, and meta-analysis of these studies). We have dismissed RCTs conducted in non-intensive care unit (ICU) populations like postoperative patients or those with cancer and stroke. We have also considered resource-limited settings and avoided recommending costly and poorly proven therapeutic options.

Accordingly, we have recommended practices that have demonstrated clinical benefit or absence of benefit, in large RCTs with clinical end points, of VTE, or complications due to use of prophylactic therapy. The commonest studied surrogate end point in trials is DVT diagnosed by venous Doppler or some other investigation. The clinically relevant primary outcomes in studies include symptomatic DVT, symptomatic pulmonary embolism (PE), mortality, and bleeding as the secondary outcome.

Each member of the expert panel was asked to give a strong recommendation or a conditional recommendation for each relevant clinical decision. For conditional recommendations, the rationale for this has been stated (plausible but minimal data or no clinical outcome data). These recommendations are restricted to the prevention of VTE (DVT and PE) in adult critically ill patients. We have excluded diagnosis or treatment of DVT and PE and pediatric population.

The panel will attempt to update the recommendations on a regular basis, but at the same time, readers should keep themselves apprised with the fast-emerging data.

Descriptive Review

The approach to DVT prevention essentially requires two separate risk evaluations, the risk of DVT vs the risk of bleeding. Prophylaxis is strongly indicated when the risk of thrombosis is high with low bleeding risk, and DVT prophylaxis with use of anticoagulants must be avoided in those with low DVT risk and high bleeding risk. DVT prophylaxis options include early passive and active mobilization, and use of pharmacological agents and mechanical devices. Clinicians should institute appropriate DVT prophylaxis as per the perceived risk of DVT vs the perceived risks of pharmacological agents.

Summary of Recommendations

A. General Considerations

1. *Risk Stratification*

1.1 *All critically ill patients in the ICU should be considered to be at moderate to high risk for DVT.*
We are unable to recommend the use of any specific scoring systems or cutoff values of any of the scoring systems for risk stratification of DVT in critically ill patients. However, we recommend considering the presence of following factors as high risk for development of VTE in ICU patients: Use of mechanical ventilation, need for vasopressors, platelet transfusion, presence of septic shock, use of a central venous catheter (CVC), use of sedatives and paralytic agents, age >60 years, prolonged immobilization, end-stage renal disease (ESRD), longer length of ICU stay (≥3.5 days).
Patients having even one of the above-listed factors should be considered at a higher risk for developing DVT, and more the number of factors present, the risk is considered to be higher.

Strong recommendation given by all *11 panelists.*

1.2 *All patients should be evaluated for bleeding risk. As there is no bleeding risk scoring system which is validated for ICU patients, the panel recommends analysis of the number of bleeding risk factors by obtaining a detailed history, clinical examination, and investigation.*
Bleeding risk increases with presence of coagulopathy (platelets <50,000/cmm, INR >1.5, aPTT >1.5 times the normal), a recent or scheduled planned/emergency procedure or surgery, presence of recent or ongoing bleeding episodes, and risk of bleed in a vital area like the airway, intraocular, or the central nervous system (CNS).

Strong recommendation given by all *11 panelists.*

2. *Choice of Prophylaxis*

2.1 *All critically ill patients should receive pharmacological thromboprophylaxis for DVT prevention if the ratio of DVT risk to risk of bleeding is acceptable, and there is no other contraindication.*

Strong recommendation is given by eight panelists. Three panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data of development of DVT in the absence of chemoprophylaxis.

2.2.1 *Panel recommends using either unfractionated heparin (UFH) low-molecular-weight heparin (LMWH) or Fondaparinux for DVT prophylaxis.*

Strong recommendation is given by seven panelists. The remaining four panelists chose to give a conditional recommendation in the absence of adequate evidence on clinical outcome data.

2.2.2 *For acute critically ill patients, LMWH are preferred over direct oral anticoagulants (DOACs) for DVT prophylaxis.*

Strong recommendation is given by nine panelists. Two panelists chose to provide a conditional recommendation in the absence of adequate evidence on clinical outcome data.

2.3.1 *In critically ill medical patients who cannot receive pharmacological VTE prophylaxis because of some contraindication, the panel recommends using mechanical method of thromboprophylaxis [intermittent pneumatic compression (IPC) device or graduated compression stockings (GCS)].*

Strong recommendation is given by eight panelists. Three panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

2.3.2 *The panel recommends using IPC devices as the choice for mechanical thromboprophylaxis for VTE. If IPC is not available, use GCS.*

Strong recommendation is given by eight panelists but rest three chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

2.4 *Panel recommends against the routine use of combined mechanical plus pharmacological prophylaxis for DVT prevention.*

Strong recommendation agreed by all 11 panelists.

2.5 *VTE prophylaxis should continue until the patient is discharged from the ICU.*

Strong recommendation is given by six panelists but the remaining five panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

2.6.1   Routine placement of endovascular (IVC) filters for prevention of thromboembolism, in patients with proximal DVT cannot be recommended.

Strong recommendation agreed by all 11 panelists.

2.6.2   Panel encourages patients to mobilize as soon as possible post-DVT, as it may be associated with lesser complications.

Strong recommendation is given by nine panelists, but two of the panelists said it is plausible, and due to poor literature, they gave a conditional recommendation.

B. Special Considerations

3.1   Panel recommends using the subclavian vein (SV) as a preferred site for insertion for central venous catheters to prevent DVT followed by internal jugular vein (IJV). Femoral vein (FV) should be chosen as the least preferred site for the same reason. Consider all other risk factors associated with various sites for central venous cannulation before deciding upon the site of cannulation.

Strong recommendation is given by seven panelists. The remaining four chose to give a conditional recommendation due to nonavailability of adequate evidence from large clinical trials and meta-analysis.

3.2   In patients of trauma, the panel recommends the initial use of mechanical prophylaxis for DVT prevention in severe trauma (including traumatic brain injury [TBI], spinal cord injury, blunt abdominal trauma). Once the risk of increase in size of hematoma/onset of fresh bleeding has been judged to be acceptable, chemical prophylaxis can be considered after 24–48 hours of ICU admission.

Strong recommendation is given by seven panelists. The remaining four chose to give a conditional recommendation as evidence from large clinical trials and meta-analysis is lacking.

3.3   Panel recommends early use of UFH or LMWH in critically ill surgical patients. Mechanical prophylaxis should be used until the risk of bleeding is high, postsurgery.

Strong recommendation is given by all 11 panelists.

3.4   Panel recommends initiating pharmacological VTE prophylaxis as quickly as feasible after high-risk cardiac surgical procedures for patients with no risk of life-threatening bleeding.

Strong recommendation is given by eight panelists. The remaining three chose to give a conditional recommendation as clinical outcome data is insufficiently convincing.

3.5   Patients with sepsis must receive daily chemoprophylaxis against DVT. Chemoprophylaxis includes once daily LMWH vs twice or thrice daily UFH.

Strong recommendation is given by all 11 panelists.

3.6   In patients with renal failure, prophylactic anticoagulation therapy for a short duration for DVT and VTE is recommended, the decision to proceed to a prolonged therapeutic anticoagulation needs to be critically evaluated individually.

In critically ill patients with renal failure, especially with a creatinine clearance of <30 mL/minute, use of UFH or Dalteparin or any LMWH that has a low degree of renal metabolism, must be preferred.

Strong recommendation is given by all 11 panelists.

3.7   All patients with heart failure with a low bleeding risk should receive LMWH or Fondaparinux.

Strong recommendation is given by nine panelists but the remaining two chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

3.8.1   In case of ischemic stroke, chemical prophylaxis should be initiated for all the patients with low bleeding risk, within 24 hours of admission.

Strong recommendation is given by three panelists but the remaining eight chose to give a conditional recommendation due to absence of adequate evidence on clinical outcome data.

3.8.2   In cases of hemorrhagic stroke and neurosurgical patients, chemical prophylaxis can be considered after 24–48 hours and after clinical, radiological, and neurosurgical review.

Strong recommendation is given by three panelists but the remaining eight chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

3.9   All critically ill pregnant patients should receive thrombo-prophylaxis with LMWH or UFH if the risk of bleeding is low. In those with a high bleeding risk, use of mechanical device for DVT prophylaxis should be considered.

Strong recommendation is given by all 11 panelists.

3.10.1   All severe and critically ill COVID-19 patients have a high risk of VTE, thus use of pharmacological prophylaxis of VTE is strongly recommended, in the absence of contraindications.

Strong recommendation is given by all 11 panelists.

3.10.2   In severe or critically ill COVID-19 patients at high risk of bleeding or with active bleeding contraindicating temporarily pharmacological thromboprophylaxis, it is recommended to use mechanical prophylaxis for VTE prevention.

Strong recommendation is given by all 11 panelists.

3.10.3   We recommend use of standard anticoagulation dose for prevention of VTE in critically ill patients with COVID-19 disease. All severe and critically ill COVID-19 patients have a high risk of VTE, so prevention of VTE is strongly recommended in absence of contraindication.

Strong recommendation is given by all 11 panelists.

A. General Considerations

1. Risk Stratification in a Critically Ill Patient

Varied scoring systems have been used to assess the risk of VTE in a hospitalized patient and the risk of bleeding associated with pharmacological prophylaxis for DVT. Also, the development of DVT is potentially life-threatening[4] for critically ill patients on mechanical ventilator, in cardiac and respiratory failure, or in shock, as the occurrence of PE in this set of patients will decompensate the already compromised system.

1.1 DVT Risk Stratification (Table 1):

Due to the heterogeneity of ICU population studied in various studies, it is difficult to identify precisely which ICU patients are vulnerable to develop a DVT. No validated risk stratification score has been developed till date, specific for ICU patients.

The complex, 30-item Caprini model applied in the PROF-ETEV trial[5] for risk stratification of 777 critically ill patients calculated that 83% of ICU patients were in the "very high risk" category (8.5–11.6% in-hospital incidence of VTE). A retrospective cohort analysis of 4,844 patients,[6] validated using this model in surgical ICU patients, with lower scores corresponding with a lesser risk of VTE, and higher scores (>8) corresponding with higher risk; However, it does not include the specific risk factors of DVT in ICU like mechanical ventilation, shock, blood transfusion, platelet transfusion, and presence of CVC. Similar findings were found in a retrospective cohort study of 2,127 cancer patients admitted to the post-surgical ICU, with patients having a Caprini score >10 at highest risk of VTE.[7]

Others score like Padua Prediction Score, The Geneva Risk Score, and International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) Risk Score have been studied in medical patients but still do not cover all the risk factors of critically ill patients (Table 2).[8–10]

Cook et al.[11] studied 261 patients with a mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score of 25.5, in a prospective cohort analysis and found the DVT prevalence as 2.7% in ICU admission, with the DVT incidence of 9.6%.

Four risk factors were identified for ICU-acquired DVT:

1. Personal or family history of VTE,
2. Vasopressor use,
3. End-stage renal failure, and
4. Platelet transfusion.

Also patients with DVT were found to have a longer duration of mechanical ventilation and longer length of ICU and hospital stay, compared to the patients without DVT.[11]

However, Kaplan et al.[12] found a much higher incidence of DVT (37.2%) in a multicenter prospective study of 113 patients with severe sepsis. Seventy-seven percent of the patients included were on MV and 54% required vasopressors with an average APACHE II score of 18.2. Patients were either on chemoprophylaxis (80.5%), warfarin (2.7%), or sequential compression devices (SCDs). The overall incidence of VTE (all lower and upper limb DVT and symptomatic) was seen in 37.2%, with 3.5% of symptomatic PE (with or without DVT). Sepsis-induced marked proinflammatory and prothrombotic systemic milieu is the probable cause of higher incidence of VTE in this group.[12]

DETECT-DVT[13] registry found an incidence of DVT in nine out of 278 patients. Seven out of these nine patients had not received any thromboprophylaxis, with data missing for the remaining two patients. The authors encourage use of thromboprophylaxis in DVT prevention and implementation of internal audits in hospitals to monitor and control the incidence of symptomatic DVT in Indian septic patients.[13]

Another cohort of 3,746 medical and surgical critically ill patients found a 7.7% incidence of VTE, despite receiving pharmacological thromboprophylaxis with either LMWH or UFH at standard doses. They reported increased body mass index (BMI), a personal or family history of VTE, and being on vasopressors as independent risk factors for failure of thromboprophylaxis.[14]

A recent systematic review and meta-analysis or VTE[15] found a probable association of VTE with moderate certainty, with older age (>60 years); elevated C-reactive protein >10 mg/L, D-dimer >500 ng/mL at baseline, and fibrinogen levels (>400 mg/dL); tachycardia (>100 beats/minute); thrombocytosis (>350 × 10^9/L); leukocytosis (>11 × 10^9/L); fever (temperature >38–39.5°C); leg edema; lower Barthel Index score (≤9); immobility

(confinement to bed for >72 hours or >7 days or bedridden or nonambulatory); paresis; previous history of VTE; thrombophilia (familial or acquired disorder of the hemostatic system); malignancy; critical illness; and infections (including cellulitis, pneumonia, and sepsis).

Viarasilpa et al.[16] have designed a prediction score (the ICU-VTE score) after obtaining data from 37,050 patients in a retrospective cohort study. The score consisted of six independent predictors: presence of CVC (5 points), more than or equal to 4 days of immobilization (4 points), prior history of VTE (4 points), mechanical ventilation (2 points), lowest hemoglobin during hospitalization greater than or equal to 9 gm/dL (2 points), and platelet count at admission greater than 250,000/µL (1 point). A score of 0–8 was found to have a low (0.3%) risk of VTE, whereas a score of 9–14 (22%) and 15–18 (2%) were considered to be intermediate (3.6%) and high risk (17.7%) for VTE, respectively.

However, the vast majority of critically ill patients should be assumed to be at a moderate to high risk for DVT.[17–19]

We do not recommend the use of any specific cutoff values of any scoring system for risk stratification of DVT. Following factors should be considered in addition to other scoring systems when risk stratifying a critically ill patient for VTE:

- Mechanical ventilation
- Need of vasopressors
- Platelet transfusion
- Septic shock
- Use of CVC
- Use of sedatives and paralytic agents
- Prolonged immobilization (≥4 days)
- ESRD
- Longer length of stay in the ICU (≥3.5 days)[20]
- Age >60 years[15]
- Past history suggestive of DVT
- Increased BMI (>40 kg/m^2)

Patients having even one of the above factors should be considered at an increased risk for VTE, and more the factors, greater is the risk for development of VTE.

Recommendation

1.1 All critically ill patients in the ICU should be considered to be at moderate to high risk for DVT.

Strong recommendation is given by all 11 panelists.

1.2 Bleeding risk stratification

It is required to evaluate the patient for the probable bleeding risk before starting prophylactic anticoagulation. Detailed history concerning risk factors for bleeding must be obtained from every patient planned for VTE chemoprophylaxis. Data to estimate chances of bleeding in critically ill patients is limited, and most clinical data come from studies on patients receiving therapeutic anticoagulation mainly for atrial fibrillation. Very few studies have evaluated the same in patients receiving prophylactic anticoagulation, but none of them have been extensively studied in ICU patients.

Kuijer et al. proposed a bleeding risk prediction score to be calculated to be instituted before starting anticoagulation in patients with VTE. The score could be calculated with three easily obtainable clinical variables (age, sex, malignancy), and patients with a score more than 3 were considered to be at a high bleeding risk.[21]

Table 1: Lists various studies predicting risk of DVT[5,11,12]

Study	Design	Patients	Aim/objective	Risk factors for DVT	Conclusion	Limitations
PROF-ETEV trial (Garcia-Olivarez et al., 2014)	Single-day point prevalence	777 total 62% medical 30% surgical and 7% trauma	High risk/moderate/low risk of DVT	Vasopressor Acute cardiac and respiratory pathology Mechanical ventilation	High risk of DVT but low rate of appropriate prophylaxis	Limited factors studied
Cook et al. (2005)	Prospective cohort	261	Prevalence of incidence and risk factors for proximal DVT	Personal/family history • ESRD • Platelet transfusion • Vasopressor	Medical-surgical critically ill are at risk of DVT	Trauma and orthopedic patients not involved
Kaplan et al. (2015)	Multicenter and prospective	113	Sepsis is risk factor for DVT?	Presence of CVC ICU-stay Age Mechanical ventilation need	Severe sepsis and septic shock have high incidence of VTE	Small size Previous history of DVT not included Severe sepsis is outdated now

Table 2: Lists the DVT risk predicting scores[8–10]

Factors	Padua Prediction Score	The Geneva Risk Score (revised)	IMPROVE and IMPROVED Risk Score
Previous VTE	✓	✓	✓
Malignancy	✓	✓	✓
Mobility	✓		✓ paralysis
Thrombophilia	✓		✓
Age	✓ 70	✓ 65	✓
Hemoptysis	✓	✓	
Mechanical ventilation	×	×	×
Platelet transfusion	×	×	×
Vasopressor	×	×	×
Renal failure	×	×	×
Surgery or fracture within 1 month	✓	✓	
Unilateral lower limb swelling	✓	✓	
Obesity	✓ BMI>30		
Ongoing hormonal treatment	✓		
Pain on palpitation	✓	✓	
Heart/respiratory failure	✓		
D-dimer			✓
ICU admission			✓
Heart rate		✓ 75–94/minute	
Limitations with scoring system	Yet to validate in large prospective study	Not to diagnose but to guide work-up and testing of PE and not DVT	Only limited factors are studied

RIETE Registry identified six independent variables for identifying the risk of major bleeding within 3 months of administering anticoagulant therapy in patients with acute VTE—age >75 years, recent bleeding, cancer, creatinine >1.2 mg/dL, anemia, and PE on presentation.[22]

Decousus et al.[23] assessed 15,156 acutely ill medical patients in a multinational cohort taken from IMPROVE and detected a cumulative incidence of bleeding (both major and nonmajor bleeding) as 3.2%, within 14 days of hospital admission. Eleven risk factors detected at hospital admission were independently associated with increased bleeding events: active gastroduodenal ulcer, bleeding during the 3 months prior to admission, platelet count $<50 \times 10^9$ at admission, advanced age ≥85 years, ICU stay, active malignancy, male sex, CVC usage, rheumatic disease, liver failure, and renal failure.[23] These risk factors were consolidated together to form a new IMPROVE bleeding risk score, which helps to predict the risk of clinically important bleeding at hospital admission for an individual patient (Tables 3 and 4).

Despite few limitations, IMPROVE bleeding score helps identify high-risk patients with a score of >7, and these are the patients we need to be cautious about. However, further validation of this score is required in critically ill patients.

Another retrospective analysis[24] of a large database of 327,578 nonsurgical patients ≥40 years of age with ≥2 days of hospitalization found major bleeding rate of 1.8% and minor bleeding risk of 7.1%. Strong predictors identified for major bleeding were preindex

Table 3: Factors in IMPROVE bleeding score (acutely ill medical patients)[23]

Risk factors	Points
Moderate renal failure (GFR 30–59 vs >60 mL/minute/m^2)	1
Male vs Female	1
Age, 40–84 vs <40	1.5
Current cancer	2
Rheumatic disease	2
Central venous catheter	2
ICU/CCU	2.5
Hepatic failure	2.5
Age >85	3.5
Platelet count <50,000	4
Bleeding 3 months before admission	4
Active gastroduodenal bleeding	4.5

Table 4: Rate of bleeding varies as per the IMPROVE score[23]

Risk score	Percentage of bleeding
1	0.5%
4	1.6%
7	4.1%
15	14%

gastroduodenal ulcer, thromboembolic stroke, blood dyscrasias, liver disease, and rehospitalization. Other minor predictors identified were higher age, group male gender, and hospital stay of ≥3 days.

A retrospective cohort study[25] of 3,358 cancer patients found gastrointestinal cancer site, an admission for anemia, morbid obesity (BMI ≥40), thrombocytopenia (<150,000/mm^3), and low hemoglobin on admission, as risk factors on admission for bleeding.

A meta-analysis[15] of three studies including 160,142 patients found a probable association with the following factors for the risk of bleeding with moderate certainty: older age (≥65 years), sex (male), anemia as reason for admission, morbid obesity (≥40 kg/m^2), low hemoglobin (<13 g/dL in men and <11.5 g/dL in women), gastroduodenal ulcers, rehospitalization, critical illness, thrombocytopenia (<50 × 10^9/L), blood dyscrasias (presence of any bleeding disorder on admission), hepatic disease, renal failure, antithrombotic medication, and presence of a CVC.

Recommendation

1.2 All patients should be evaluated for bleeding risk. As there is no bleeding risk scoring system which is validated for ICU patients, the panel recommends analysis of the number of bleeding risk factors by obtaining a detailed history, clinical examination, and investigation.

Strong recommendation is given by all 11 panelists.

Risk factors for bleeding include:

- Presence of coagulopathy (platelets <50,000/cmm, INR >1.5, aPTT >1.5 times the normal),
- A recent or scheduled elective/emergency procedure or surgery,
- Presence of recent or ongoing bleeding episodes, and

- Risk of bleed/active bleed in critical areas like the airway, intraocular, or the CNS.
- Admission for anemia
- Hepatic or renal disease
- Older age (>65 years)
- BMI (>40 kg/m^2)

2. Choice of Prophylaxis

2.1 Selection of Patient

The best assessment model for risk assessment of VTE vs the risk of bleeding has not yet been defined. Choice of thromboprophylaxis should evaluate the potential risk of VTE in a critically ill patient, along with the risk for bleeding. Although it is a daily struggle to maintain a difficult balance between bleeding and thrombosis, a meticulous decision considering all factors should be taken.

However, the vast majority of ICU patients should be assumed to be at a moderate to high risk for DVT.[17–19] Also, not receiving early thromboprophylaxis without obvious reasons, within the first 24 hours of ICU admission, has been shown to have a higher risk of mortality.[4]

Alhazzani et al.[26] conducted a meta-analysis of all critically ill patient trials who received heparin prophylaxis. A total of 7,226 patients were studied in a total of seven trials, and it was clear that compared with placebo, any heparin thromboprophylaxis reduced the rates of DVT [pooled risk ratio, 0.51 (95% CI, 0.41, 0.63); $p <0.0001$; $I = 77\%$] and PE [risk ratio, 0.52 (95% CI, 0.28, 0.97); $p = 0.04$; $I = 0\%$] but not symptomatic DVT [risk ratio, 0.86 (95% CI, 0.59, 1.25); $p = 0.43$]. The risk of major bleeding and of mortality was same in both the groups.

Recommendation

2.1 All critically ill patients should receive pharmacological thromboprophylaxis for DVT prevention if the ratio of DVT risk to the risk of bleeding is acceptable, and there is no other contraindication.

Strong recommendation is given by eight panelists but remaining three panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data of development of DVT in absence of chemoprophylaxis.

2.2 Selection of Chemical Thromboprophylaxis

Choosing the right agent for thromboprophylaxis is also an important factor to be considered in sick, critically ill patients. Factors such as ease of administration and presence of organ failures are to be taken into consideration. Not many trials have shown an advantage of one agent over another, and a decision based on host factors and hospital policy should be taken. (Table 5 lists the doses of commonly used drugs for thromboprophylaxis in the ICU). Also to take into consideration the ease of monitoring of response in unstable patients, especially with the use of LMWH, as a poor response can lead to a failed prophylaxis.

In an RCT of 156, critically ill patients undergoing elective surgery were randomized to receive LMWH 40 mg, once daily and a placebo injection, vs UFH 5000 IU twice daily. Each patient was postoperatively confirmed clinically and with an ultrasound Doppler for the presence of DVT. Of the 156 patients in total, there was no difference in efficacy of LMWH vs Heparin. However, minor complications like hematoma and surgical site infection were more in the heparin group.[27]

Table 5: Commonly used drugs for DVT prophylaxis

Drug	Dose	Route
Unfractionated heparin	5000 units	Subcutaneous, twice daily
Enoxaparin	40 mg	Subcutaneous, once daily
Dalteparin	5000 IU	Subcutaneous, once daily
Fondaparinux	2.5 mg	Subcutaneous, once daily

Cook et al.[28] conducted a multicenter RCT of 3,764 patients comparing Dalteparin once daily, plus Placebo once daily vs UFH 5000 IU twice daily for VTE prophylaxis. They found a reduction in PE (1.3 vs 2.3%, $p = 0.01$), but no difference in the rate of DVT (5.1 vs 5.8%, $p = 0.57$) with dalteparin as compared with heparin.

An RCT of 3,746 medical-surgical critically ill patients (secondary analysis of PROTECT database) found no significant difference in the incidence of proximal leg DVT with Dalteparin compared with UFH. However, a significant decrease in the risk of PE was observed with the use of Dalteparin.[29]

A meta-analysis by Alhazzani et al. of seven randomized trials involving 7,226 critically ill medical-surgical patients found that use of any heparin prophylaxis compared with that of placebo decreases the rate of DVT and PE, but not of symptomatic DVT. Risk of major bleeding and mortality rates were similar with the use of UFH and LMWH. However, as compared with UFH, use of LMWH reduced the rate of PE and symptomatic PE but did not decrease the rate of DVT, symptomatic DVT, major bleeding, or mortality.[26]

Another meta-analysis of eight RCTs (5,567 patients) found a beneficial effect of LMWH over UFH, in reducing the risk of any DVT (RR 0.84, 95% CI 0.71–0.98, $p = 0.03$) with a net clinical benefit (RR 0.90, 95% CI 0.83–0.97, $p = 0.01$). No statistically significant difference was found in the risk of any PE, major bleeding, or mortality.[30]

A meta-analysis of 12 RCTs with 8,622 patients found that the risk of DVT was similar in patients receiving prophylaxis with UFH (5000 U sc bid) or LMWH (either enoxaparin sc 30 mg bid/40 mg qd) (OR, 1.16; 95% CI, 0.68–2.11). Both the treatment groups had similar major bleeding risk, even in critically ill patients with a high risk of bleeding.[31]

Recommendation

2.2.1 *Panel recommends using either UFH or LMWH or Fondaparinux for DVT prophylaxis.*

Strong recommendation is given by seven panelists but the remaining four panelists chose to give a conditional recommendation in the absence of adequate evidence on clinical outcome data.

No studies have been conducted on the use of current DOACs for VTE prevention in ICU patients. Four trials though have examined the role of DOACs in the prevention of VTE in medically ill patients—ADOPT trial, MAGELLAN trial, APEX trial, and MARINER trial.[32–35] However, all the four trials were constructed to evaluate extended vs standard duration of thromboprophylaxis and not to determine which is the best agent for prophylaxis of VTE.

DOACs may be beneficial against symptomatic VTE, all VTE; however, they also have been associated with a higher risk of bleeding numbers.[36]

Overall, there is paucity of evidence to suggest the role of DOACs in VTE prevention in the ICU.

Recommendation

2.2.2 *For acute critically ill patients, LMWH are preferred over DOACs for DVT prophylaxis.*

Strong recommendation is given by nine panelists but the remaining two panelists chose to give a conditional recommendation in the absence of adequate evidence on clinical outcome data.

2.3 Mechanical Method of Thromboprophylaxis

ICU patients who carry a high risk for VTE, with a contraindication for use of anticoagulation (active bleeding, intracranial bleed), or risk of bleeding is high (presence of coagulopathy), use of mechanical thromboprophylaxis alone may be proposed. Mechanical devices provide compression to a limb with the help of calf or thigh length garments and thus increase blood velocity in the lower limb deep veins, reducing blood stasis and also stimulating fibrinolysis. Whenever mechanical thromboprophylaxis is used, a pharmacological agent for VTE prophylaxis should be initiated as soon as the bleeding risk decreases.

Mechanical methods of DVT prophylaxis include:

- GCS—Compression stockings with graduated pressure (highest at the ankle and lower proximally) prevent venous stasis due to pressure difference.
- Intermittent Pneumatic Compression Devices (IPCD)—Alternate inflation and deflation of the cuffs tied over the calf and the thigh muscles to improve venous drainage.

  Sequential compression devices are a type of IPCDs with split pockets of inflation on the sleeves, which helps to squeeze in a "milking action." The pockets inflate sequentially starting from the most distal pockets, followed by the subsequent pockets in the same manner, to promote distal to proximal venous drainage.

  Intermittent Pneumatic Compression Devices are noninvasive, and easy to use, but more costly, and may be accompanied with discomfort, reduced mobility, and skin injury.

  Commercially available mechanical pumps have an automatic cycle, that is, there are 12 seconds for inflation for venous emptying alternating with 48 seconds for deflation to allow venous filling. The pressure varies in between 30 and 60 mm Hg.

- Mechanical foot pumps—The third type of compression device are mechanical foot pumps, which by intermittent plantar compression increase the flow of blood in the leg veins. Very rarely used.

  In cases of using mechanical prophylaxis, a Cochrane review explains that GCS effectively reduced the rates of DVT in hospitalized surgical patients, whether used alone or in combination with chemical chemoprophylaxis.[37] In eight studies which compared the effectiveness of GCS with no other prophylaxis, DVT rates reduced from 26 to 12%.[37]

Recommendation

2.3.1 *In critically ill medical patients who cannot receive pharmacological VTE prophylaxis because of some contraindication, the panel recommends using mechanical method of thromboprophylaxis (IPCD or GCS).*

Strong recommendation is given by eight panelists but the remaining three panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

In a cohort study of 798 ICU patients analyzed prospectively, it was shown that IPCD use significantly lowered the incidence of VTE, compared to no mechanical thromboprophylaxis. However, use of GCS was not associated with decreased VTE incidence. This effect was consistent irrespective of the type of heparin used for prophylaxis, history of recent surgery, or recent trauma.[38]

A recent systematic review and meta-analysis showed that use of the IPCD significantly reduces the incidence of VTE as compared to no thromboprophylaxis. Also use of the IPC showed lower incidence of VTE compared to the use of GCS.[39]

Also occurrence of pressure injuries are a significant complication of GCS noted in postsurgical ICU patients.[40]

Recommendation

2.3.2 The panel recommends using IPC devices as the choice for mechanical thromboprophylaxis for VTE. If IPC is not available, use GCS.

Strong recommendation is given by eight panelists but the remaining three panelists chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

2.4 Combining Different Methods of Thromboprophylaxis

A Cochrane Collaboration meta-analysis found that IPC plus pharmacologic prophylaxis reduces symptomatic PE (1.2 vs 2.9%) but not DVT (2.9 vs 6.2%) compared to pharmacologic prophylaxis alone. However, the studies included were not limited to critically ill patients.[41]

A pragmatic, randomized, multicenter trial (PREVENT Trial)[42] showed that the use of adjunctive IPCD (used for a median of 22 hours daily) along with pharmacological thromboprophylaxis did not significantly reduce the incidence of proximal lower-limb DVT as compared to use of pharmacologic thromboprophylaxis alone, in 2,003 critically ill patients. Incidence of proximal DVT was 37 of 957 patients (3.9%) in the pneumatic compression group (pharmacological + IPC) vs 41 of 985 patients (4.2%) in the control (pharmacological) group [relative risk, 0.93; 95% confidence interval (CI), 0.60–1.44; $p = 0.74$]. However, in this trial, the DVT rate was lower than expected in the control group.

Recommendation

2.4 Panel recommends against the routine use of combined mechanical plus pharmacological prophylaxis for DVT prevention.
Strong recommendation is agreed by all 11 panelists.

2.5 Duration of DVT Prophylaxis

The optimal degree of ambulation that provides protection or reduces the risk of DVT is unknown. Although data do not support routinely extending the duration of thromboprophylaxis in critically ill medical patients beyond admission, few selected populations may probably benefit from thromboprophylaxis for an extended duration (e.g., stroke, nonambulatory patients, patients not able to independently ambulate or patients mechanically ventilated who are admitted to acute rehabilitation unit for physical therapy or for ventilator weaning).

Three RCTs and a recent meta-analysis found nonsuperiority of extended course of thromboprophylaxis with DOACs (30–42 days of the DOAC including rivaroxaban, betrixaban, and apixaban), compared to a standard course of LMWH (7–14 days of the LMWH mainly enoxaparin) in acutely ill inpatient treatment, in terms of

mortality, symptomatic DVT. However, patients on DOACs had a slightly increased risk of major bleeding.[34,35,43]

Although extended duration prophylaxis (i.e, beyond the acute hospital stay) has proven to be beneficial in some high-risk surgical patients (e.g., patients with total hip replacement), similar benefits have not been consistently observed in patients admitted for critical illnesses.[11,12]

A systematic review with 18 articles, including 7 RCTs, found no high-quality evidence supporting ambulation as a sole effective prophylaxis for VTE in hospitalized patients. Ambulation cannot be considered as an adequate prophylaxis for VTE nor as an adequate reason to discontinue pharmacologic prophylaxis for VTE during the duration of patient's hospital admission.[44]

Similar studies have not been done in the critically ill population.

Recommendation

2.5 VTE prophylaxis should continue until the patient is discharged from the ICU.

Strong recommendation is agreed by all 11 panelists.

2.6 Prevention of PE (post-DVT)

There is no strong evidence to prove efficacy of IVC filter in preventing VTE, and its use is controversial. They may be considered in patients with an active DVT below the level of IVC and an absolute contraindication to anticoagulants for the prevention of DVT.

Decouses H et al. did a two-by-two factorial design study in 400 patients and showed the initial beneficial effect of using vena caval filters in high-risk patients with proximal vein thrombosis was negated by an excess of recurrent DVT with no change in the mortality.[45]

Few selected patients in the very high-risk category might benefit from optional IVC filters.[46] In patients with absolute contraindications for the use of anticoagulation and a high risk of VTE recurrence, IVC filters might be tried.[46] In fact, in one study, IVC filter placement was associated with higher 30 days mortality in patients with VTE in whom anticoagulation was contraindicated.[47]

Also, an IVC filter is associated with complications which include DVT and IVC thrombosis with potential extension into the renal veins, filter fracture, strut perforation, and embolization, high cost, and rare removal (<10% of the time in a 2013 survey in trauma patients).[48]

Recommendation

2.6.1 Routine placement of endovascular (IVC) filters for prevention of thromboembolism, in patients with proximal DVT cannot be recommended.

Strong recommendation is agreed by all 11 panelists.

Meta-analysis of 13 studies including a total of 3,269 patients suggests that compared to complete bed rest, early mobilization in patients with lower extremity DVT, on anticoagulation does not elevate the risk of PE or DVT progression.[49]

The American College of Chest Physicians (ACCP) guideline recommendations for early mobilization are also based on a small number of studies and therefore subject to bias.[50] Mobilization may also be advantageous in reducing pain and edema associated with DVTs; However, larger scale studies with higher patient numbers are needed to confirm these outcomes.

Recommendation

2.6.2 *Panel encourages patients to mobilize as soon as possible post-DVT, as it may be associated with lesser complications.*

Strong recommendation is given by nine panelists but two of the panelists stated that it is plausible but due to poor literature, they gave a conditional recommendation.

B. Special Considerations

1. Catheter-related DVT—Site of Cannulation

In a multicenter randomized control trial,[51] central venous cannulation of FV was found to be associated with significantly increased incidence of catheter-related thrombosis when compared to SV (21.5% in FV vs 1.9% in SV with *p* <0.001). FV cannulation was identified as an independent risk factor for venous thrombosis (odds ratio 14.42). Not only was there higher incidence of thrombosis in FV, it was also associated with higher incidence of complete venous thrombosis when compared to SV catheterizations (6% in FV vs 0% in SV; *p* <0.01).[51]

In a prospective analysis, Malinoski et al. evaluated the association between the catheterization site and risk of thrombosis. Various catheter types like multi-lumen catheters, introducer sheaths, hemodialysis catheters, and peripherally inserted central catheters were assessed.[52] The authors showed that IJV cannulation resulted in a 7-fold higher risk of venous thrombosis, when compared to SV. SV cannulation had the least association with catheter related DVT (9/1,000 CVC days in SV vs 61/1,000 CVC days in IJV). After regression analysis, the authors showed that IJV cannulation was an independent predictor of catheter-related thrombosis (odds ratio 6.0 with 95% CI). IJV cannulation as a risk factor for catheter-related DVT has been confirmed in multiple other studies.[53,54]

In a Cochrane review comparing CVC insertion routes, subclavian was proved to be the preferred route instead of femoral for short term CVC insertion because of less thrombotic complications.[55]

A multicenter RCT of 3,471 catheters used in adult ICUs found lower risk of symptomatic thrombosis in the subclavian route of catheterization, as compared to the jugular and FV catheterization.[56]

Right-sided vessels are commonly used for cannulation. Critically ill patients might require catheters multiple times, necessitating multiple site cannulations. In a large observational study involving cancer patients,[57] left-sided SV cannulations were associated with a higher incidence of venous thrombosis (87.5% vs 62%), compared to the right side.

Recommendation

3.1 *Panel recommends using the SV as a preferred site for insertion for central venous catheters to prevent DVT followed by IJV. FV should be chosen as the least preferred site for the same reason. Consider all other risk factors associated with various sites for central venous cannulation before deciding about the site of cannulation.*

Strong recommendation is given by seven panelists but the remaining four chose to give a conditional recommendation due to nonavailability of adequate evidence from large clinical trials and meta-analysis.

2. Trauma

International multicenter trauma registry–based study[3] and metanalysis[1] of seven RCTs showed that DVT prophylaxis with any method is recommended in major trauma. Early chemical thromboprophylaxis within 48 hours did not significantly increase the bleeding complications, and it appears that prophylaxis decreases asymptomatic DVT but has no effect on PE and mortality. Thus, it is safe to start chemoprophylaxis early. Interestingly, most VTE occurred despite adequate prophylaxis being given.[58,59]

In acute spinal cord injury, both LMWH and UFH are safe and have lower incidence of PE. Also, pharmacological prophylaxis is better than mechanical prophylaxis. In terms of prevention of symptomatic VTE or fatal PE, there is no difference between LMWH and UFH. LMWH should be withheld on the morning of surgery and restarted within 24 hours after the surgery once stable for bleeding risk.[60–62] No difference was seen between different LMWH in prevention of DVT or bleeding risk.[63]

Studies have shown that severe TBI patients without coagulopathy, with a neurologically stable injury and with low hemorrhagic risk clinically or on repeat imaging, starting chemoprophylaxis at 24–48 hours, doesn't increase bleeding risk.[64,65] There is no strong evidence for preferred agent and dose of chemical VTE prophylaxis. Chemoprophylaxis reduces clinical VTE but no difference in PE in TBI patient.[2]

Early prophylactic IVC filter placement after major trauma is not found to reduce the incidence of symptomatic PE or death at 90 days as compared to no filter placement.[66]

In a recent multicenter, RCT, 240 severely injured patients (with an Injury Severity Score >15) who had a contraindication to the use of prophylactic anticoagulation were assigned to either placement of a vena cava filter within the first 72 hours after admission or to no filter placement. Early prophylactic vena cava filter did not result in a significantly reduced incidence of symptomatic PE or death, compared to no IVC filter placement (13.9% in the vena cava filter group and 14.4% in the control group; hazard ratio, 0.99; 95% CI, 0.51–1.94; *p* = 0.98). Early prophylactic use of an IVC filter after major trauma did not lead to a lower incidence of symptomatic PE or death at 90 days as compared to no filter placement.[67]

Recommendation

3.2 *In patients of trauma, the panel recommends the initial use of mechanical prophylaxis for DVT prevention in severe trauma (including TBI, spinal cord injury, blunt abdominal trauma). Once the risk of increase in size of hematoma/onset of fresh bleeding has been judged to be acceptable, chemical prophylaxis can be considered after 24–48 hours of ICU admission.*

Strong recommendation is given by seven panelists but the remaining four panelists chose to give a conditional recommendation as evidence from large clinical trials and meta-analysis is lacking.

3. Critically Ill Surgical Patients

In a meta-analysis of seven RCTs and one systemic review, it is observed that LMWH and UFH are effective for VTE and PE prevention in critically ill patients undergoing major surgery. Low molecular weight heparin was found to be better than UFH for decreasing PE and symptomatic PE. Incidence of major bleeding events and mortality rates were not significantly

affected by the type of heparin thromboprophylaxis in the ICU setting.[26–28]

Recommendation

3.3 *Panel recommends early use of UFH or LMWH in critically ill surgical patients. Mechanical prophylaxis should be used until the risk of bleeding is high, postsurgery.*

Strong recommendation is agreed by all 11 panelists.

4. Cardiac Surgery Patients

In one meta-analysis including observational studies ($n = 49$), RCTs ($n = 16$), and meta-analysis ($n = 3$), use of VTE prophylaxis decreased the risk of PE (patients were evaluated for clinical signs and PE was confirmed by pulmonary angiography or perfusion scan) [relative risk (RR), 0.45; 95% CI, 0.28–0.72; $p = 0.0008$] or symptomatic VTE (RR, 0.44; 95% CI, 0.28–0.71; $p = 0.0006$) without significant heterogeneity, as compared to the control.[68]

High-risk cardiac surgery patients, previous history of VTE, obesity, left or right ventricular failure, prolonged bed rest, mechanical ventilation >24 hours, use of a CVC, and blood transfusion were common factors associated with an increased VTE risk.[4,68]

There was no increased incidence of bleeding or cardiac tamponade requiring reoperation in this group of patients with the use of pharmacological VTE prophylaxis, without use of any systemic anticoagulation for other indications.

Recommendation

3.4 *Panel recommends initiating pharmacological VTE prophylaxis as quickly as feasible after high-risk cardiac surgical procedures for patients with no risk of life-threatening bleeding.*

Strong recommendation is given by eight panelists but the remaining three chose to give a conditional recommendation as clinical outcome data are insufficiently convincing.

5. Severe Sepsis[69–71]

Septic patients admitted to the ICU were found to have a 12.5% incidence of VTE in a retrospective study of 335 patients and a 37% incidence of VTE in a prospective study of 113 patients.[12,72]

Trials for VTE prophylaxis in the ICU mainly include an undifferentiated group of critically ill; thus, evidence in support of use of pharmacologic prophylaxis in septic patients is indirect. A large prospective RCT compared the incidence of VTE in septic patients who received activated drotrecogin alfa (DrotAA) (now not used). The patients were randomized to receive either placebo or UFH or LWMH. The study found that the overall safety profile was acceptable in patients with severe sepsis given DrotAA and suggested to carefully weigh the discontinuation of heparin in this group of patients.[73]

Recommendation

3.5 *Patients with sepsis must receive daily chemoprophylaxis against DVT. Chemoprophylaxis includes once daily LMWH vs twice or thrice daily UFH.*

Strong recommendation is agreed by all 11 panelists.

6. Renal Failure

Renal failure leads to endothelial injury/dysfunction, initial platelet hyperreactivity, increased fibrin formation, and reduced fibrinolytic system activity, thus increasing the risk of VTE. Also platelet aggregation and adhesion are reduced as a consequence of progressive renal dysfunction, thus increasing the risk of bleeding as well.[74] Hence, critically ill patients with renal insufficiency should be given individualized VTE prophylaxis in the context of the thromboembolic and hemorrhagic risks and should be closely monitored.

Low-molecular-weight heparin are more dependent on renal function for clearance than UFHs, and thus, bioaccumulation of LMWH is increased in patients with renal insufficiency, further increasing the chances of bleeding.[75]

In a retrospective, single-center, cohort study including 460 ICU patients with renal impairment, DVT prophylaxis was administered with either enoxaparin or UFH, it was found that use of enoxaparin for thromboprophylaxis in renally impaired critically ill patients, was associated with an increase in major bleeding events compared to UFH.[76]

Two small recent prospective observational studies consisting of 19 patients[77] and 138 ICU patients,[78] with an estimated creatinine clearance under 30 mL/minute, found that Dalteparin did not bioaccumulate. Dalteparin has not been shown to increase the risk of bleeding in critically ill patients with severe renal insufficiency. However, the effect of LMWHs on the bleeding risk in this group of patients other than that of Dalteparin remains controversial.

Recommendation

3.6 *In patients with renal failure, prophylactic anticoagulation therapy for a short duration for DVT and VTE is recommended, and the decision to proceed to a prolonged therapeutic anticoagulation needs to be critically evaluated individually.*

In critically ill patients with renal failure, especially with creatinine clearance is <30 mL/minute, use of UFH or Dalteparin or any LMWH that has a low degree of renal metabolism, should be preferred.

Strong recommendation is agreed by all 11 panelists.

7. Heart Failure[79]

Acutely ill medical patients with congestive heart failure, who are immobilised and have one or more of the following additional risk factors (active cancer, previous VTE, sepsis, acute neurologic disease, or inflammatory bowel disease) should receive thromboprophylaxis with either LMWH or UFH or Fondaparinux.

Recommendation

3.7 *All patients with heart failure with a low bleeding risk should receive LMWH or Fondaparinux.*

Strong recommendation is given by nine panelists but the remaining two chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

8. Neurological Conditions

In a review of 16 trials with 23,043 patients, higher doses of UFH and LMWH decreased the risk of DVT and PE, but this benefit is counterbalanced by an increased risk of intracranial or extracranial bleeding. Standard doses of UFH and LMWH were beneficial without an increased risk of ICH.[80] Both aspirin and mechanical prophylaxis have been found to be suboptimal to prevent VTE.[81]

Trials for use of VTE prophylaxis in acute hemorrhagic stroke are limited and with a smaller sample size. Patients admitted with primary intracerebral haemorrhage and TBI should be given IPC

immediately on admission, followed by either low-dose LMWH or UFH 3–4 days after stroke onset or 24 hours after injury or surgery, respectively, and once the bleeding has stopped.[82]

In a trial, 68 patients with primary intracerebral haemorrhage were randomized to receive low-dose heparin (5,000 units three times daily) beginning on either day 2, 4, or 10 after the onset of stroke or placebo.[83] Those administered with heparin from day 2 had a significantly reduced incidence of PE, with no increase in rebleeding.

In another double-blind RCT of patients undergoing elective neurosurgery patients demonstrated that LMWH given within 24 hours after surgery along with compression stockings more effectively prevented the occurrence of VTE than use of compression stockings alone (RR 0.51; 95% CI 0.33–0.80).[84] The incidence of major bleeding events including intracranial bleeding was similar in both the groups, thus concluding that enoxaparin can be safely be administered within 24 hours after elective neurosurgery.

Recommendations

3.8.1 *In case of ischemic stroke, chemical prophylaxis should be initiated for all the patients with low bleeding risk, within 24 hours of admission.*

Strong recommendation is given by three panelists but the remaining eight chose to give a conditional recommendation due to absence of adequate evidence on clinical outcome data.

3.8.2 *In cases of hemorrhagic stroke and neurosurgical patients, chemical prophylaxis can be considered after 24–48 hours and after clinical, radiological, and neurosurgical review.*

Strong recommendation is given by three panelists but the remaining eight chose to give a conditional recommendation due to nonavailability of convincing clinical outcome data.

9. Pregnancy[85–89]

Pregnancy is a hypercoagulable state, and risk for VTE in critically ill pregnant patients is high. ACCP and American College of Obstetricians and Gynecologists recommend clinical surveillance and anticoagulant prophylaxis in the postpartum period for mothers with a single previous episode of VTE caused by a transient provoking risk factor which is no longer existing.

There are no studies regarding use of DVT prophylaxis in critically ill pregnant patients and the choice of agent. UFH and LMWH use has been found to be safe and effective in pregnancy.[90,91]

Recommendation

3.9 *All critically ill pregnant patients should receive thromboprophylaxis with LMWH or UFH if the risk of bleeding is low. In those with a high bleeding risk, use of mechanical device for DVT prophylaxis should be considered.*

Strong recommendation is agreed by all 11 panelists.

10. COVID-19 Disease

COVID-19 disease has been recognized as a hypercoagulable state, and several interim consensus statements recommended the use of a pharmacologic agent for thromboprophylaxis in COVID-19 hospitalized patients. Also, 3.5 times higher rates of failure of LMWH prophylaxis have been noted in patients with COVID-19.[92]

Recommendation

3.10.1 *All severe and critically ill COVID-19 patients have a high risk of VTE, so use of pharmacological prophylaxis of VTE is strongly recommended in the absence of contraindications.*

Strong recommendation is agreed by all 11 panelists.

3.10.2 *In severe or critically ill COVID-19 patients at high risk of bleeding or with active bleeding contraindicating temporarily pharmacological thromboprophylaxis, it is recommended to use mechanical prophylaxis for VTE prevention.*

Strong recommendation is agreed by all 11 panelists.

Three large international clinical trial platforms harmonized their study protocols and outcomes to study the role of therapeutic-dosed anticoagulation with heparin in critically ill patients with COVID-19. These trials consist of the ACTIV-4 (NCT04505774), REMAP-CAP (NCT02735707), and the ATTACC (NCT04372589) and are collectively called multiplatform RCT.

However, after an interim analysis and following the advice from the data and safety monitoring board, this multiplatform trial discontinued further enrolment for ICU patients on December 19, 2020, as the criteria of prespecified futility boundary for the primary end point was reached, and it was not possible to exclude the potential for harm.[93] From the data of 1,098 critically ill patients, the survival to hospital discharge and number of days free from organ support were similar in patients receiving pharmacological anticoagulation in therapeutic dose or in usual care prophylactic dose.[94] The incidence of major bleeding was 3.8% in patients on therapeutic-dose anticoagulation vs 2.3% in those on usual-care prophylactic dose of anticoagulation.[94]

INSPIRATION trial studied the efficacy and safety of intermediate-dose thromboprophylaxis with LMWH ($n = 276$ patients) vs the standard-dose thromboprophylaxis ($n = 286$ patients) and found no difference in the primary efficacy outcome (a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days) in the intermediate-dose group [126 (45.7%) patients] and in the standard-dose prophylaxis [126 (44.1%)]. The incidence of major bleeding was seven (2.5%) events in the intermediate-dose group and four (1.4%) in the group receiving standard-dose prophylaxis.[95]

Recommendation

3.10.3 *We recommend use of standard anticoagulation dose for prevention of VTE in critically ill patients with COVID-19 disease. All severe and critically ill COVID-19 patients have a high risk of VTE, so prevention of VTE is strongly recommended in absence of contraindication.*

Strong recommendation is agreed by all 11 panelists.

Orcid

Bharat G Jagiasi ● https://orcid.org/0000-0002-3068-1201
Akshaykumar A Chhallani ● https://orcid.org/0000-0001-6321-3167
Subhal B Dixit ● https://orcid.org/0000-0002-1441-0807
Rishi Kumar ● https://orcid.org/0000-0003-3733-9182
Rahul A Pandit ● https://orcid.org/0000-0002-5846-3708
Deepak Govil ● https://orcid.org/0000-0002-4624-1614
Shirish Prayag ● https://orcid.org/0000-0002-5474-4393
Kapil G Zirpe ● https://orcid.org/0000-0002-8140-727X
Rajesh C Mishra ● https://orcid.org/0000-0001-6305-5998
Gunjan Chanchalani ● https://orcid.org/0000-0001-8429-8526
Farhad N Kapadia ● https://orcid.org/0000-0003-1837-1144

REFERENCES

1. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): National Academies Press (US); 2011. DOI: 10.17226/13058.

2. Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress. Arch Intern Med 2012;172(21):1628–1633. DOI: 10.1001/2013.jamainternmed.56.

3. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost 2002;28 (Suppl. 2):3–13. DOI: 10.1055/s-2002-32312.

4. Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011;140(6):1436–1446. DOI: 10.1378/chest.11-1444.

5. García-Olivares P, Guerrero JE, Galdos P, Carriedo D, Murillo F, Rivera A. PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain. Intensive Care Med 2014;40(11):1698–1708. DOI: 10.1007/s00134-014-3442-1.

6. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, et al. Validation of the caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg 2015;150(10):941–948. DOI: 10.1001/jamasurg.2015.1841.

7. Xu JX, Dong J, Ren H, Chen XJ, Yang Y, Chen RX, et al. Incidence and risk assessment of venous thromboembolism in cancer patients admitted to intensive care unit for postoperative care. J BUON 2018;23(1):248–254. PMID: 29745099.

8. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8(11):2450–2457. DOI: 10.1111/j.1538-7836.2010.04044.x.

9. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006;144(3):165–171. DOI: 10.7326/0003-4819-144-3-200602070-00004.

10. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014;3(6):e001152. DOI: 10.1161/JAHA.114.001152.

11. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33(7):1565–1571. DOI: 10.1097/01.ccm.0000171207.95319.b2.

12. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, et al. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest 2015;148(5):1224–1230. DOI: 10.1378/chest.15-0287.

13. Ramakrishnan N, Detect-Dvt Investigators. Prophylaxis and incidence of symptomatic deep vein thrombosis in Indian patients with sepsis: DETECT-Deep Vein Thrombosis Registry. Indian J Crit Care Med 2017;21(11):765–771. DOI: 10.4103/ijccm.IJCCM_205_17.

14. Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. Crit Care Med 2015;43(2):401–410. DOI: 10.1097/CCM.0000000000000713.

15. Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood 2020;135(20):1788–1810. DOI: 10.1182/blood.2019003603.

16. Viarasilpa T, Panyavachiraporn N, Marashi SM, Van Harn M, Kowalski RG, Mayer SA. Prediction of symptomatic venous thromboembolism in critically ill patients: the ICU-venous thromboembolism score. Crit Care Med 2020;48(6):e470–e479. DOI: 10.1097/CCM.0000000000004306.

17. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl. 2):e227S–e277S. DOI: 10.1378/chest.11-2297.

18. Gibson CD, Colvin MO, Park MJ, Lai Q, Lin J, Negassa A, et al. Prevalence and predictors of deep vein thrombosis in critically ill medical patients who underwent diagnostic duplex ultrasonography. J Intensive Care Med 2020;35(10):1062–1066. DOI: 10.1177/0885066618813300.

19. Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M, et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus 2015;13(4):559–568. DOI: 10.2450/2015.0277-14.

20. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005;51(2–3):70–78. DOI: 10.1016/j.disamonth.2005.02.003.

21. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159(5):457–460. DOI: 10.1001/archinte.159.5.457.

22. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100(1):26–31. DOI: 10.1160/TH08-03-0193.

23. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139(1):69–79. DOI: 10.1378/chest.09-3081.

24. Mahan CE, Spyropoulos AC, Fisher MD, Fields LE, Mills RM, Stephenson JJ, et al. Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. Clin Appl Thromb Hemost 2013;19(5):504–512. DOI: 10.1177/1076029612470967.

25. Patell R, Gutierrez A, Rybicki L, Khorana AA. Identifying predictors for bleeding in hospitalized cancer patients: a cohort study. Thromb Res 2017;158:38–43. DOI: 10.1016/j.thromres.2017.08.005.

26. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013;41(9):2088–2098. DOI: 10.1097/CCM.0b013e31828cf104.

27. De A, Roy P, Garg VK, Pandey NK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinol 2010;21(1):57–61. DOI: 10.1097/MBC.0b013e3283333505.

28. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364(14):1305–1314. DOI: 10.1056/NEJMoa1014475.

29. Li G, Cook DJ, Levine MAH, Guyatt G, Crowther M, Heels-Ansdell D, et al. Competing risk analysis for evaluation of dalteparin versus unfractionated heparin for venous thromboembolism in medical-surgical critically ill patients. Medicine 2015;94(36):e1479. DOI: 10.1097/MD.0000000000001479.

30. Beitland S, Sandven I, Kjærvik LK, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive care medicine 2015;41(7):1209–1219. DOI: 10.1007/s00134-015-3840-z.

31. Park J, Lee JM, Lee JS, Cho YJ. Pharmacological and mechanical thromboprophylaxis in critically ill patients: a network meta-analysis

of 12 trials. J Korean Med Sci 2016;31(11):1828–1837. DOI: 10.3346/jkms.2016.31.11.1828.

32. McCullough M, Kholdani C, Zamanian RT. Prevention of deep vein thrombosis and pulmonary embolism in high-risk medical patients. Clin Chest Med 2018;39(3):483–492. DOI: 10.1016/j.ccm.2018.04.002.

33. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365(23):2167–2177. DOI: 10.1056/NEJMoa1110899.

34. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368(6):513–523. DOI: 10.1056/NEJMoa1111096.

35. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375(6):534–544. DOI: 10.1056/NEJMoa1601747.

36. Rali P, Gangemi A, Moores A, Mohrien K, Moores L. Direct-acting oral anticoagulants in critically ill patients. Chest 2019;156(3):604–618. DOI: 10.1016/j.chest.2019.05.025.

37. Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2018;11(11):CD001484. DOI: 10.1002/14651858.CD001484.pub4.

38. Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM, et al. Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: a multiple propensity scores adjusted analysis. Chest 2013;144(1):152–159. DOI: 10.1378/chest.12-2028.

39. Wang Y, Huang D, Wang M, Liang Z, et al. Can intermittent pneumatic compression reduce the incidence of venous thrombosis in critically ill patients: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2020;26:1076029620913942. DOI: 10.1177/1076029620913942.

40. Hobson DB, Chang TY, Aboagye JK, Lau BD, Shihab HM, Fisher B, et al. Prevalence of graduated compression stocking-associated pressure injuries in surgical intensive care units. J Crit Care 2017;40:1–6. DOI: 10.1016/j.jcrc.2017.02.016.

41. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby G, Reddy DJ, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev 2016;9(9):CD005258. DOI: 10.1002/14651858.CD005258.pub3.

42. Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. New Engl J Med 2019;380(14):1305–1315. DOI: 10.1056/NEJMoa1816150.

43. Neumann I, Izcovich A, Zhang Y, Rada G, Kahn SR, Spencer F, et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv 2020;4(7):1512–1517. DOI: 10.1182/bloodadvances.2019000840.

44. Lau BD, Murphy P, Nastasi AJ, Seal S, Kraus PS, Hobson DB, et al. Effectiveness of ambulation to prevent venous thromboembolism in patients admitted to hospital: a systematic review. CMAJ Open 2020;8(4):E832–E843. DOI: 10.9778/cmajo.20200003.

45. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risqued'EmboliePulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338(7):409–415. DOI: 10.1056/NEJM199802123380701.

46. Wehrenberg-Klee E, Stavropoulos SW. Inferior vena cava filters for primary prophylaxis: when are they indicated? Semin Intervent Radiol 2012;29(1):29–35. DOI: 10.1055/s-0032-1302449.

47. Turner TE, Saeed MJ, Novak E, Brown DL. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open 2018;1(3):e180452. DOI: 10.1001/jamanetworkopen.2018.0452.

48. Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013;173(7):513–517. DOI: 10.1001/jamainternmed.2013.343.

49. Liu Z, Tao X, Chen Y, Fan Z, Li Y. Bed rest versus early ambulation with standard anticoagulation in the management of deep vein thrombosis: a meta-analysis. PLoS One. 2015;10(4):e0121388. DOI: 10.1371/journal.pone.0121388.

50. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl. 2):e419S–e496S. DOI: 10.1378/chest.11-2301. [Erratum in: Chest 2012;142(6):1698–1704.]

51. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, et al; French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. Journal of the American Medical Association 2001;286(6):700–707. DOI: 10.1001/jama.286.6.700.

52. Malinoski D, Ewing T, Bhakta A, Schutz R, Imayanagita B, Casas T, et al. Which central venous catheters have the highest rate of catheter-associated deep venous thrombosis: a prospective analysis of 2,128 catheter days in the surgical intensive care unit. J Trauma Acute Care Surg 2013;74(2):454–460; discussion 461–462. DOI: 10.1097/TA.0b013e31827a0b2f.

53. Hrdy O, Strazevska E, Suk P, Vach R, Karlik R, Jarkovsky J, et al. Central venous catheter-related thrombosis in intensive care patients-incidence and risk factors: a prospective observational study. Biomed Pap Med FacUnivPalacky Olomouc Czech Repub 2017;161(4):369–373. DOI: 10.5507/bp.2017.034.

54. Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med 1995;23(1):52–59. DOI: 10.1097/00003246-199501000-00011.

55. Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev 2012;2012(3):CD004084. DOI: 10.1002/14651858.CD004084.pub3.

56. Parienti JJ, Mongardon N, Mégarbane B, Mira JP, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. New Engl J Med 2015;373(13):1220–1229. DOI: 10.1056/NEJMoa1500964.

57. De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997;86(2):101–113. DOI: 10.1016/s0049-3848(97)00054-6.

58. Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev 2013;(3):CD008303. DOI: 10.1002/14651858.CD008303.pub2.

59. Gunning AC, Maier RV, de Rooij D, Leenen LPH, Hietbrink F. Venous thromboembolism (VTE) prophylaxis in severely injured patients: an international comparative assessment. Eur J Trauma Emerg Surg 2019. DOI: 10.1007/s00068-019-01208-z.

60. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma 2003;54(6):1116–1124; discussion 1125–1126. DOI: 10.1097/01.TA.0000066385.10596.71.

61. Chiou-Tan FY, Garza H, Chan KT, Parsons KC, Donovan WH, Robertson CS, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. Am J Phys Med Rehabil 2003;82(9):678–685. DOI: 10.1097/01.phm.0000083671.27501.47.

62. Halim TA, Chhabra HS, Arora M, Kumar S. Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an

Indian perspective. Spinal Cord 2014;52(7):547–550. DOI: 10.1038/sc.2014.71.

63. DiGiorgio AM, Tsolinas R, Alazzeh M, Haefeli J, Talbott JF, Ferguson AR, et al. Safety and effectiveness of early chemical deep venous thrombosis prophylaxis after spinal cord injury: pilot prospective data. Neurosurg Focus 2017;43(5):E21. DOI: 10.3171/2017.8.focus17437.

64. Margolick J, Dandurand C, Duncan K, Chen W, Evans DC, Sekhon MS, et al. A systematic review of the risks and benefits of venous thromboembolism prophylaxis in traumatic brain injury. Can J Neurol Sci 2018;45(4):432–444. DOI: 10.1017/cjn.2017.275.

65. Farooqui A, Hiser B, Barnes SL, Litofsky NS. Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. J Neurosurg 2013;119(6):1576–1582. DOI: 10.3171/2013.8.JNS13424.

66. Ho KM, Rao S, Honeybul S, Zellweger R, Wibrow B, Lipman J, et al. A multicenter trial of vena cava filters in severely injured patients. N Engl J Med. 2019;381(4):328–337. DOI: 10.1056/NEJMoa1806515.

67. Ho KM, Holley A, Lipman J. Vena Cava filters in severely-injured patients: one size does not fit all. Anaesth Crit Care Pain Med 2019;38(4):305–307. DOI: 10.1016/j.accpm.2019.07.003.

68. Ho KM, Bham E, Pavey W. Incidence of venous thromboembolism and benefits and risks of thromboprophylaxis after cardiac surgery: a systematic review and meta-analysis. J Am Heart Assoc 2015;4(10):e002652. DOI: 10.1161/JAHA.115.002652.

69. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Journal of the American Medical Association 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.

70. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41(2):580–637. DOI: 10.1097/CCM.0b013e31827e83af.

71. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36(1):296–327. DOI: 10.1097/01.CCM.0000298158.12101.41 [Erratum in: Crit Care Med 2008;36(4):1394–1396].

72. Hanify JM, Dupree LH, Johnson DW, Ferreira JA. Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis. J Crit Care 2017;37:206–210. DOI: 10.1016/j.jcrc.2016.10.002.

73. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007;176(5):483–490. DOI: 10.1164/rccm.200612-1803OC.

74. Cook DJ, Douketis J, Arnold D, Crowther MA. Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Curr Opin Pulmonary Med 2009;15(5):455–462. DOI: 10.1097/mcp.0b013e32832ea4.

75. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688–698. DOI: 10.1056/NEJM199709043371007.

76. DeBiase C, Giuliano CA, Doshi M, Ganoff M, Alexander Paxton R. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients. Pharmacotherapy 2021;41(5):424–429. DOI: 10.1002/phar.2518.

77. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005;20:357–363. DOI: 10.1016/j.jcrc.2005.09.009.

78. Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008;12:R32. DOI: 10.1186/cc6810.

79. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(Suppl. 6):381S–453S. DOI: 10.1378/chest.08-0656.

80. Kamphuisen PW, Giancarlo A. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Thromb Res 2007;119(3):265–274. DOI: 10.1016/j.thromres.2006.03.010.

81. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005;3(6):1187–1194. DOI: 10.1111/j.1538-7836.2005.01443.x.

82. Vergouwen MD, Roos YB, Kamphuisen PW. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury. Curr Opin Crit Care 2008;14(2):149–155. DOI: 10.1097/MCC.0b013e3282f57540.

83. Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1991;54(5):466–467. DOI: 10.1136/jnnp.54.5.466.

84. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339(2):80–85. DOI: 10.1056/NEJM199807093390204.

85. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J ThrombHaemost 2008;6(4):632–637. DOI: 10.1111/j.1538-7836.2008.02921.x.

86. James A; Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011;118(3):718–729. DOI: 10.1097/AOG.0b013e3182310c4c.

87. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(Suppl. 1):1–203. DOI: 10.1111/j.1471-0528.2010.02847.x. [Erratum in: BJOG 2015;122(5):e1].

88. Lockwood C, Wendel G; Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011;118(3):730–740. DOI: 10.1097/AOG.0b013e3182310c6f.

89. Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and Bayesian meta-analysis. British Medical Association 2017;359:j4452. DOI: 10.1136/bmj.j4452.

90. Jacobson BF, Virendra R, Dara P, Sayre T. Safety and efficacy of enoxaparin in pregnancy: a systematic review and meta-analysis. Adv Ther 2020;37(1):27–40. DOI: 10.1007/s12325-019-01124-z.

91. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106(2):401–407. DOI: 10.1182/blood-2005-02-0626.

92. Dutt T, Simcox D, Downey C, McLenaghan D, King C, Gautam M, et al. Thromboprophylaxis in COVID-19: anti-FXa-the missing factor? Am J Respir Crit Care Med 2020;202(3):455–457. DOI: 10.1164/rccm.202005-1654LE.

93. National Heart, Lung, and Blood Institute NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients. 2020.

Available from: https://www.nhlbi.nih.gov/news/2020/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients.

94. REMAP-CAP Investigators, ACTIV-4a Investigators; ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. New Engl J Med 2021;385(9):777–789. DOI: 10.1056/NEJMoa2103417.

95. INSPIRATION Investigators. Sadeghipour P, Talasaz AH. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. Journal of the American Medical Association 2021. DOI: 10.1001/jama.2021.4152.